To appraise the clinical and cost effectiveness of avelumab within its marketing authorisation for urothelial cancer
Status In progress
Process STA 2018
ID number 3735

Provisional Schedule

Expected publication 25 August 2021

Project Team

Project lead Louise Jafferally

Email enquiries

Evidence Review Group / Assessment Group Health Economics Research Unit and Health Services Research Unit, University of Aberdeen


Companies sponsors Merck Serono Ltd (avelumab)
Others Department of Health and Social Care
  NHS England
  Welsh Government
Patient carer groups Action Bladder Cancer UK
  Fight Bladder Cancer
Professional groups Association of Cancer Physicians
  British Uro-Oncology Group
  Cancer Research UK
  Royal College of Physicians
  Royal College of Radiologists
  The Urology Foundation


Comparator companies None
General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare products Regulatory Agency
  Scottish Medicines Consortium
  Welsh Health Specialised Services Committee
Relevant research groups Institute of Cancer Research


Key events during the development of the guidance:

Date Update
17 June 2021 Committee meeting: 2
06 May 2021 - 27 May 2021 Appraisal consultation
14 April 2021 Committee meeting: 1
03 August 2020 Invitation to participate
04 May 2020 - 03 June 2020 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
06 February 2020 In progress. Topic is now in progress

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance